All News

In a new study, poor sleep was linked to an increased risk of life-threatening flare-ups in people with chronic obstructive pulmonary disease (COPD).

A panel of experts at the SLEEP 2022 conference argued against considering race a risk factor for health complications and disrupted sleep, saying that being on the receiving end of racial discrimination is the true risk factor.

Efficacy of biologics was observed in both men and women with psoriasis, although female patients reported a greater impact from the disease on quality of life (QOL) and lower treatment satisfaction.

Abbott Nutrition has resumed formula production in its Michigan plant to address the nationwide formula shortage; 2 distinct strains of monkeypox may indicate rapid, undetected spread nationwide; the overturn of Roe v Wade could have an effect on in vitro fertilization and genetic testing.

Kim A. Reiss, MD, assistant program director of the Hematology/Oncology Fellowship Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses pancreatic cancer research she presented at the 2022 American Society of Clinical Oncology Annual Meeting.

A novel prognostic model based on N 6-methyladenosine-associated long non-coding RNAs demonstrated accuracy in determining high- and low-risk disease, suggesting the associated risk value may have potential as a novel biomarker.

Joel W. Neal, MD, PhD, associate professor, Division of Oncology, Stanford Cancer Institute, is lead investigator on the COSMIC-021 trial, which is investigating cabozantinib plus atezolizumab vs cabozantinib alone in patients with advanced non–small cell lung cancer (NSCLC) as a possible second-line treatment beyond chemotherapy.

Results presented at the American Society of Clinical Oncology Annual Meeting showed a 21.4-month advantage for autologous stem cell transplant (ASCT) over a common triplet therapy in progression-free survival (PFS) but no advantage in overall survival (OS).

Practice-changing data from the DESTINY-Breast04 study, presented during the 2022 Annual Meeting of the American Society of Clinical Oncology in Chicago, show that trastuzumab deruxtecan reduced the risk of disease progression or death by 50% compared with chemotherapy for human epidermal growth factor receptor-2 (HER2)–low patients with both hormone receptor (HR)–positive and HR-negative disease.

Gary Owens, MD, president of Gary Owens Associates, explains the importance of shared decision making and patient-centered care in pulmonary arterial hypertension (PAH).

Thanos Zomas, MD, global medical lead, Lymphoma and Leukemia, and global medical lead, Adcetris Program, at Takeda Oncology discusses updated results from the ECHELON-1 study.

Levels of the 2 markers appeared to indicate both the presence of SLE and disease activity levels.

Posters from the SLEEP 2022 conference revealed some of the interaction between idiopathic hypersomnia and different aspects of life, including weight changes and interpersonal relationships.

David R. Penberthy, MD, MBA, is medical director, Radiation Oncology, Bon Secours-Southside Medical Center in Petersburg, Virginia, and president of the Association of Community Cancer Centers for the 2022-2023 term.

TROPiCS-02, a phase 3 study, was presented during a session on breast cancer at the 2022 Annual Meeting of the American Society of Clinical Oncology.

A smartphone application designed to identify jaundice in newborns was found to have a similar success rate as the most commonly used conventional screening method.

Asthma history and olfactory, rhinorrhea, and nasal polyp endoscopy scores were identified as independent predictors of eosinophilic disease in Chinese patients with chronic rhinosinusitis with nasal polyps.

Preventing graft-versus-host disease (GVHD) after allogeneic stem cell transplant is a key aspect of patient management, but current cyclosporine concentration guidelines may not be sufficient, according to a recent study.

The researchers underscored the importance of the patient voice in the field, as some aspects of treatment can only be assessed through the patient.

Patients said they benefited from diabetes management technology, but also from social accountability.

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.

Enrique Ocio, MD, PhD, hematology department head, Marqués de Valdecilla University Hospital, Santander, Spain, discusses phase 1b trial results for subcutaneous (sub-Q) vs intravenous isatuximab, both formulations administered in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM).

The collaboration, put in place through a Memorandum of Understanding, was presented Saturday in a keynote address by WHO Cancer Control Officer André Ilbawi, MD, during the presidential symposium at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago.

Early detection of chronic kidney disease (CKD) in adolescents in minority groups can be beneficial to future treatment, according to a recent editorial.

Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.

As more treatments continue to enter the market for multiple myeloma (MM), the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.

Little data exist on the effectiveness of dupilumab in Black and Hispanic children, even though severe asthma disproportionately affects these populations.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, provides an overview of recent approvals and indications under consideration for the treatment of pediatric atopic dermatitis.

The researchers highlighted that the dermatology field is considered one of the least diverse and most competitive specialties.